MET14 exon skipping mutation and non-small cell lung cancer

doi:10.3760/cma.j.cn371439-20201207-00070

Abstract

Abstract:

The molecular mechanism of the skipping mutation of MET14 exon (METex14) is mainly that the skipping of METex14 leads to the loss of the c-Cbl tyrosine binding site, which causes the proteasome-mediated degradation of MET protein to decrease, which continuously activates the MET signal, and finally leads to tumorigenesis. The incidence of METex14 skipping mutations in non-small cell lung cancer is 3%-4%. Drugs that act on skipping mutations of METex14 include crizotinib, capmatinib, tepotinib, savolitinib, and have a high objective remission rate and good safety. However, due to gene amplification, second site mutations, bypass activation and pathological type conversion, drug resistance after targeted drug therapy requires attention.

Key words: Carcinoma, non-small-cell lung, MET exon 14 skipping mutation, Tyrosine kinase inhibitors

Zhou Ye, Yu Yan. MET14 exon skipping mutation and non-small cell lung cancer[J]. Journal of International Oncology, 2021, 48(6): 366-369.

References 35

[1]	Cufer T, Knez L. Update on systemic therapy of advanced non-small-cell lung cancer[J]. Expert Rev Anticancer Ther, 2014,14(10):1189-1203. DOI: 10.1586/14737140.2014.940327. doi: 10.1586/14737140.2014.940327
[2]	Malik R, Mambetsariev I, Fricke J, et al. MET receptor in oncology: from biomarker to therapeutic target[J]. Adv Cancer Res, 2020,147:259-301. DOI: 10.1016/bs.acr.2020.04.006.
[3]	Recondo G, Che J, Jänne PA, et al. MET targeting dysregulation in cancer[J]. Cancer Discov, 2020,10(7):922-934. DOI: 10.1158/2159-8290.Cd-19-1446. doi: 10.1158/2159-8290.CD-19-1446
[4]	Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage Ⅳlung adenocarcinomas harboring MET mutations causing exon 14 skipping[J]. Cancer Discov, 2015,5(8):842-849. DOI: 10.1158/2159-8290.Cd-14-1467. doi: 10.1158/2159-8290.CD-14-1467
[5]	Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression[J]. J Clin Oncol, 2016,34(7):721-730. DOI: 10.1200/jco.2015.63.4600. doi: 10.1200/JCO.2015.63.4600
[6]	Tong JH, Yeung SF, Chan AW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis[J]. Clin Cancer Res, 2016,22(12):3048-3056. DOI: 10.1158/1078-0432.Ccr-15-2061. doi: 10.1158/1078-0432.CCR-15-2061
[7]	Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations[J]. J Thorac Oncol, 2016,11(9):1493-1502. DOI: 10.1016/j.jtho.2016.06.004. doi: 10.1016/j.jtho.2016.06.004 pmid: 27343443
[8]	Saffroy R, Fallet V, Girard N, et al. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung[J]. Oncotarget, 2017,8(26):42428-42437. DOI: 10.18632/oncotarget.16403. doi: 10.18632/oncotarget.v8i26
[9]	Saito M, Shiraishi K, Kunitoh H, et al. Gene aberrations for precision medicine against lung adenocarcinoma[J]. Cancer Sci, 2016,107(6):713-720. DOI: 10.1111/cas.12941. doi: 10.1111/cas.2016.107.issue-6
[10]	Zheng D, Wang R, Ye T, et al. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer[J]. Oncotarget, 2016,7(27):41691-41702. DOI: 10.18632/oncotarget.9541. doi: 10.18632/oncotarget.v7i27
[11]	Liu SY, Gou LY, Li AN, et al. The unique characteristics of MET exon 14 mutation in chinese patients with NSCLC[J]. J Thorac Oncol, 2016,11(9):1503-1510. DOI: 10.1016/j.jtho.2016.05.016. doi: 10.1016/j.jtho.2016.05.016
[12]	Lee GD, Lee SE, Oh DY, et al. MET exon 14 skipping mutations in lung adenocarcinoma: clinicopathologic implications and prognostic values[J]. J Thorac Oncol, 2017,12(8):1233-1246. DOI: 10.1016/j.jtho.2017.04.031. doi: 10.1016/j.jtho.2017.04.031
[13]	Gow CH, Hsieh MS, Wu SG, et al. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population[J]. Lung Cancer, 2017,103:82-89. DOI: 10.1016/j.lungcan.2016.12.001. doi: 10.1016/j.lungcan.2016.12.001
[14]	Kwon D, Koh J, Kim S, et al. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: an analysis of intratumoral MET status heterogeneity and clinicopathological characteristics[J]. Lung Cancer, 2017,106:131-137. DOI: 10.1016/j.lungcan.2017.02.008. doi: 10.1016/j.lungcan.2017.02.008
[15]	Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors[J]. Cancer Discov, 2015,5(8):850-859. DOI: 10.1158/2159-8290.Cd-15-0285. doi: 10.1158/2159-8290.CD-15-0285 pmid: 25971938
[16]	Cortot AB, Kherrouche Z, Descarpentries C, et al. Exon 14 deleted MET receptor as a new biomarker and target in cancers[J]. J Natl Cancer Inst, 2017,109(5). DOI: 10.1093/jnci/djw262.
[17]	Descarpentries C, Leprêtre F, Escande F, et al. Optimization of routine testing for MET exon 14 splice site mutations in NSCLC patients[J]. J Thorac Oncol, 2018,13(12):1873-1883. DOI: 10.1016/j.jtho.2018.08.2023. doi: S1556-0864(18)33038-7 pmid: 30195702
[18]	Kim EK, Kim KA, Lee CY, et al. Molecular diagnostic assays and clinicopathologic implications of MET exon 14 skipping mutation in non-small-cell lung cancer[J]. Clin Lung Cancer, 2019,20(1):e123-e132. DOI: 10.1016/j.cllc.2018.10.004. doi: 10.1016/j.cllc.2018.10.004
[19]	Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer[J]. JAMA Oncol, 2019,5(2):173-180. DOI: 10.1001/jamaoncol.2018.4305. doi: 10.1001/jamaoncol.2018.4305 pmid: 30325992
[20]	Reungwetwattana T, Liang Y, Zhu V, et al. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable[J]. Lung Cancer, 2017,103:27-37. DOI: 10.1016/j.lungcan.2016.11.011. doi: S0169-5002(16)30527-X pmid: 28024693
[21]	Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations[J]. J Clin Oncol, 2016,34(8):794-802. DOI: 10.1200/jco.2015.62.0674. doi: 10.1200/JCO.2015.62.0674
[22]	Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration[J]. Nat Med, 2020,26(1):47-51. DOI: 10.1038/s41591-019-0716-8. doi: 10.1038/s41591-019-0716-8
[23]	Middleton G, Popat S, Fletcher P, et al. National lung matrix trial (NLMT): first results from an umbrella phase Ⅱ trial in advanced non-small cell lung cancer (NSCLC)[J]. J Thorac Oncol, 2019,14(10):S7. DOI: 10.1016/j.jtho.2019.08.060. doi: 10.1016/j.jtho.2019.08.060
[24]	Lee C, Usenko D, Frampton GM, et al. MET 14 deletion in sarco-matoid non-small-cell lung cancer detected by next-generation sequencing and successfully treated with a MET inhibitor[J]. J Thorac Oncol, 2015,10(12):e113-e114. DOI: 10.1097/jto.0000000000000-645. doi: 10.1097/JTO.0000000000000645
[25]	Baltschukat S, Engstler BS, Huang A, et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation[J]. Clin Cancer Res, 2019,25(10):3164-3175. DOI: 10.1158/1078-0432.Ccr-18-2814. doi: 10.1158/1078-0432.CCR-18-2814 pmid: 30674502
[26]	Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or -amplified non-small-cell lung cancer[J]. N Engl J Med, 2020,383(10):944-957. DOI: 10.1056/NEJMoa2002787. doi: 10.1056/NEJMoa2002787
[27]	Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations[J]. N Engl J Med, 2020,383(10):931-943. DOI: 10.1056/NEJMoa2004407. doi: 10.1056/NEJMoa2004407
[28]	Lu S, Fang J, Li XY, et al. Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14⁺)[J]. J Clin Oncol, 2020,38(15_suppl):9519. DOI: 10.1200/JCO.2020.38.15_suppl.9519. doi: 10.1200/JCO.2020.38.15_suppl.9519
[29]	Suzawa K, Offin M, Lu D, et al. Activation of KRAS mediates resistance to targeted therapy in MET exon 14-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2019,25(4):1248-1260. DOI: 10.1158/1078-0432.Ccr-18-1640. doi: 10.1158/1078-0432.CCR-18-1640 pmid: 30352902
[30]	Rotow JK, Gui P, Wu W, et al. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer[J]. Clin Cancer Res, 2020,26(2):439-449. DOI: 10.1158/1078-0432.Ccr-19-1667. doi: 10.1158/1078-0432.CCR-19-1667
[31]	Jamme P, Fernandes M, Copin MC, et al. Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET exon 14 skipping mutations[J]. J Thorac Oncol, 2020,15(5):741-751. DOI: 10.1016/j.jtho.2020.01.027. doi: 10.1016/j.jtho.2020.01.027
[32]	Jin W, Shan B, Liu H, et al. Acquired mechanism of crizotinib resistance in NSCLC with MET exon 14 skipping[J]. J Thorac Oncol, 2019,14(7):e137-e139. DOI: 10.1016/j.jtho.2019.04.021. doi: 10.1016/j.jtho.2019.04.021
[33]	Ou SI, Young L, Schrock AB, et al. Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping[J]. J Thorac Oncol, 2017,12(1):137-140. DOI: 10.1016/j.jtho.2016.09.119. doi: 10.1016/j.jtho.2016.09.119
[34]	Engstrom LD, Aranda R, Lee M, et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type Ⅰ MET inhibitors in nonclinical models[J]. Clin Cancer Res, 2017,23(21):6661-6672. DOI: 10.1158/1078-0432.Ccr-17-1192. doi: 10.1158/1078-0432.CCR-17-1192 pmid: 28765324
[35]	Klempner SJ, Borghei A, Hakimian B, et al. Intracranial activity of cabozantinib in MET exon 14-positive NSCLC with brain metastases[J]. J Thorac Oncol, 2017,12(1):152-156. DOI: 10.1016/j.jtho.2016.09.127. doi: S1556-0864(16)31079-6 pmid: 27693535